Is the failure of the SYMPLICITY HTN-3 trial to meet its efficacy endpoint the “end of the road” for renal denervation? Will renal denervation now land on the heap of failed technologies? I don’t think so, and Dr. Darrel Francis, the cardiologist who famously predicted that SYMPLICITY HTN-3 would not meet its endpoint, agrees.
In fact Dr. Francis told Angioplasty.Org that it would be a “grave error” if the FDA withheld renal denervation from the American people, based on this news!
OK. Do I have your attention? Continue reading